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Understanding cancer metabolism is key to revealing the
Achilles’ heel of cancer cells and providing novel therapeutic
interventions for patients. While the rerouting of metabolic
pathways during development1 or cancer transformation and
progression2–4 has been extensively characterised, the exact
dynamics of these events, their distribution and frequency in
different tumour types, and their correlation with genetic
background remain largely unknown. In a recent article
published inNature, Karen Vousden’s team assesses the effect
of serine and glycine (SG) dietary restriction in autochthonous
mouse tumour models driven by different oncogenes,5 leading
to potential areas of therapeutic intervention.
The non-essential amino acids serine and glycine are now
considered essential metabolites for some types of cancers.3,6
Serine can be imported into the cell through different
transporters or can be produced by diversion of glycolytic
glucose in the serine biosynthetic pathway (SSP).7 Exogen-
ous or de novo-synthetised serine is converted to glycine, and
by stimulating one-carbon metabolism, provides a source of
nucleotides, ATP, methylation reactions, and antioxidant
defences, such as glutathione and NAPDH.8 Cancer cells
can react to SG deprivation by triggering SSP, suppressing
aerobic glycolysis, and increasing the flux to the tricarboxylic
acid cycle. This rearrangement of metabolism supports
adaptation to oxidative stress initiated by impaired one-
carbon metabolism, and allows cells to survive under these
adverse conditions. Notably, the response to serine starvation
is regulated by p53 and, in consequence, p53− /− cells fail to
respond to SG depletion, showing severe impairment of
proliferation and cell viability associated with unbalanced
redox defence.9 Together, these lines of research indicate that
SG metabolism can be a potential target for cancer therapy.
As an alternative to selectively targeting the enzymes
responsible for SG synthesis, Maddocks et al.5 reasoned that
SG deprivation could be a powerful strategy to affect this
pathway. In their recent study, they analysed the response to
an SG-free diet in different genetically modified animal models
of lymphoma (Eμ-Myc), intestinal tumours (ApcMin/+), and
pancreatic cancer (Pdx1-cre; KRasG12D/+; trp53+/− and Pdx1-
cre; KRasG12D/+; Trp53R172H/+). These experiments indicated
that SG starvation effectively prolongs survival of Eμ-Myc and
ApcMin/+mice, which carry pre-malignant lesions since shortly
after birth. The authors also tested the impact of this restricted
diet on established malignant tumours. They developed
xenograft/allograft models by subcutaneous injection of
human colorectal carcinoma (HCT-116) or mouse Eμ-Myc
tumour cells and transferred the animals to an SG-depleted
experimental diet after the tumours were established. SG
restriction reduced tumour volume after relatively short
periods of treatment (6 days of SG-free diet in Eμ-Myc cells-
derived tumours) and this was associated with increased cell
death in the tumour core.
SG deprivation was also shown to increase mitochondrial
metabolism.10 Therefore, the authors tested the effects of SG
dietary restriction in combination with biguanides and inhibi-
tors of complex I of the electron transport chain. The results
highlighted a complex response that suggested that bigua-
nides and SG deprivationmight synergise in restricting tumour
growth when the combination effectively prevents oxidative
defence. Phenoformin indeed reduced tumour growth in
Eμ-Myc mice. However, due to its high toxicity, the use of the
more tolerable analogue metformin was required to complete
the study. Unexpectedly, in SG-deprived ApcMin/+mice, phar-
macological doses of metformin promoted tumour growth
rather than improving the anti-tumour effect. Remarkably, low-
and high-dose metformin correlated with increased or
decreased reactive oxygen species (ROS) levels, respec-
tively, indicating that the ability of metformin to synergise with
SG depletion correlates with its anti- or pro-oxidant effects. To
formally prove that increased ROS levels enhance anti-tumour
effects of the SG-free diet, the authors crossed Eμ-Myc mice
with mice deficient for Tigar, a fructose-2,6-bisphosphatase,
which limits glycolysis and favours pentose phosphate path-
ways, thus limiting ROS levels11,12 (Figure 1). The combina-
tion of Tigar deficiency and SG deprivation significantly
increased overall survival with an additive effect. As a common
mechanism of action of routine chemotherapeutic drugs is to
attack the cancer cells with high levels of ROS, it is now a
priority to test whether an SG-free diet improves efficacy of
standard anticancer therapies.
The authors then tested the effects of SG deprivation on a
model of pancreatic cancer driven by K-Ras mutation.
Surprisingly, the authors found that SG restriction did not
affect tumour growth and survival in two different models of
Kras-driven pancreatic tumours (Pdx1-cre; KRasG12D/+;
trp53+/−and Pdx1-cre; KRasG12D/+; Trp53R172H/+). Further
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analysis showed that these Kras-driven tumour models rely
heavily on SSP for SG supply, when compared to intestinal
ApcMin/+ cancers. Analysis of intravenously injected 13C-15N-
labelled serine in mice revealed that pancreatic tumours take
up serine and glycine at a similar level to healthy pancreas;
conversely, serine uptake in ApcMin/+ tumours is significantly
increased as compared to normal intestinal tissues.
Accordingly, KrasG12D-expressing cells had high levels of
SSPenzymes (PHGDH, PAST1, and PSPH), and depletion of
Kras reduced their expression (Figure 1). Expression of
KrasG12D in organoids derived from Vil1-creER;APCfl/fl intest-
inal tumours promoted conversion of glucose to serine and
thus restored their in vitro growth upon exogenous SG
deprivation. These data are in agreement with a recent study
Figure 1 The serine synthesis pathway (SSP) diverges from glycolysis utilising the intermediate 3P-glycerate, which is converted by PHGDH, PSAT-1, and PSPH into serine
and then glycine. Removal of exogenous serine and glycine causes activation of SSP, however Vousden’s study demonstrates that tumours, such as Eμ-Myc- and ApcMin/+-driven
lymphomas and intestinal lesions can be susceptible to serine and glycine (SG) deprivation. Concurrent SG dietary restriction and biguanide administration might improve
anti-tumour effects when associated with a reduction in antioxidant defence. On contrary, Kras-driven pancreatic tumours appear resistant to SG-free diet as observed from the
ability of Kras to promote expression of PHGDH, PSAT-1, and PSPH and thus boost activity of SSP. This figure is re-adapted from Amelio and Melino19
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by Kottakis et al.13 reporting that concurrent Krasmutation and
LKB1 depletion in the pancreas drives upregulation of SSP
and dependence of these cells on this biosynthetic pathway.
In conclusion, these study data highlight the complexity of
SG metabolism in cancer cells and the importance of the
mutational landscape of cancer in the response to dietary
restriction and therapeutic intervention. Indeed, SG depriva-
tion could be ineffective in tumours that exhibit an active SSP.
However, in Kras-driven tumours, the effects of SG restriction
could be limited in breast tumours characterised by PHGDH
amplification,14,15 but also in lung tumours, where NRF2 was
shown to activate SSP.16 Another important aspect is that the
effects of SG deprivation depends on the redox status of the
cell. Although the role of oxidative stress in cancer is currently
highly debated, this work shows that the effects of SG
deprivation could be potentially compromised by strategies
that prevent oxidative stress, such as antioxidants. Therefore,
any dietary intervention needs to be fine-tuned to prevent
idiosyncratic interactions. This work raises several interesting
questions. For instance, it will be interesting to assesswhether
SG-free diets can prevent tumour formation, in addition to
slowing its progression. In this context, it is intriguing to
speculate that the anticancer effects of low-protein diets or
calorie restriction17 are, at least in part, mediated by SG
restriction. Finally, it will be important to assess the mechan-
isms beyond the anticancer effects of SG starvation. An
SG-free diet affects the immune system leading to a
dysregulation of T lymphocytes, as recently suggested.18 It
will be interesting to determine whether this diet, besides
exhibiting cell-autonomous effects, can actually modulate the
immune system to fight cancer cells.
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